Jul. 21 at 2:12 AM
Telix Pharmaceuticals shares rose after the company reported strong second-quarter results and provided an upbeat outlook for 2026. Revenue reached
$247 million in the June quarter, up 7% sequentially and 21% year over year, driven by 30% annual growth in its Precision Medicine segment, which generated
$202 million in revenue. Management now expects full-year 2026 revenue and other income to exceed
$1 billion, targeting the upper end of its previous guidance range of
$950 million to
$970 million, plus
$40 million in non-reimbursable income from Regeneron.
The company also announced that the first patient has been dosed in its Phase 3 LUTEON trial evaluating TLX250-Tx for recurrent clear cell renal cell carcinoma, marking the first Phase 3 study of a carbonic anhydrase IX-targeted radiopharmaceutical therapy. Additionally, Telix raised its 2026 R&D spending guidance to between
$230 million and
$270 million to support accelerated investments in high-value clinical programs.
$TLX $REGN